C
PMCB icon

Covestor’s PharmaCyte Biotech PMCB Stock Holding History

Covestor’s Portfolio PMCB Stock Details PMCB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$0 Hold
275
– – ﹤0.01% 2665
2025
Q4 		$0 Hold
275
– – ﹤0.01% 2636
2025
Q3 		$0 Hold
275
– – ﹤0.01% 2652
2025
Q2 		$0 Hold
275
– – ﹤0.01% 2631
2025
Q1 		$0 Hold
275
– – ﹤0.01% 2611
2024
Q4 		$0 Buy
275
+49
+22% +$85 ﹤0.01% 2620
2024
Q3 		$0 Hold
226
– – ﹤0.01% 2630
2024
Q2 		$0 Hold
226
– – ﹤0.01% 2632
2024
Q1 		$1K Hold
226
– – ﹤0.01% 2076
2023
Q4 		$0 Buy
226
+37
+20% +$80 ﹤0.01% 2580
2023
Q3 		$0 Hold
189
– – ﹤0.01% 2570
2023
Q2 		$1K Buy
+189
New +$567 ﹤0.01% 2003

Other funds holding PMCB

Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

Covestor's PMCB Position: Q1 2026 in Review

Covestor held its PharmaCyte Biotech (PMCB) position steady in Q1 2026 at 275 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2665.

Covestor first reported a position in PMCB in Q2 2023 and has held it in 12 quarters since. The position peaked at $1K in Q1 2024. 32 funds tracked by Wall St. Rank hold PMCB as of Q1 2026.

  • Covestor held 275 shares of PharmaCyte Biotech worth $0 as of Q1 2026.
  • Covestor left its PharmaCyte Biotech share count unchanged in Q1 2026.
  • PharmaCyte Biotech made up ﹤0.01% of Covestor's portfolio in Q1 2026, its #2665 holding.
  • Covestor first reported a position in PharmaCyte Biotech in Q2 2023 and has held it in 12 quarters since.
  • Covestor's PharmaCyte Biotech position peaked at $1K in Q1 2024.
  • 32 funds tracked by Wall St. Rank held PharmaCyte Biotech as of Q1 2026.

Based on Covestor's 13F filing for Q1 2026, filed 5 May 2026.